Jonathan Hollick

Jonathan Hollick

Company: Breakpoint Therapeutics

Job title: Managing Director and Head of Research


Plenary Panel: How Do You Select the Best Model for Your Study & Achieve the Best Balance of Preclinical Tumour Models? 8:20 am

Moderated by: Adam Drake, Head of In Vivo Pharmacology Ichnos Science • Addressing the lack of fit-for-purpose models and the next steps to improve this • Strategies to select the most appropriate model for your cancer study • Understanding how to combine different tumour models for a study and leveraging them to get the optimal…Read more

day: Conference Day One

Decoding DNA Damage Response (DDR) Efficacy in Tumour Models to Advance Translation into the Clinic 9:20 am

• Identifying current challenges associated with evaluating DDR-targeted therapies in preclinical tumour models • Uncovering assays to assess the effects of polymerase theta in combination therapy • Exploring strategies to improve the translational relevance of DDR studiesRead more

day: Conference Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.